Targeted therapies for rare lung diseases


Avalyn is a clinical-stage biopharmaceutical company developing inhaled therapies to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases. Our lead candidate, AP01, now in a Phase 2b study, is an inhaled formulation of pirfenidone in development for the treatment of pulmonary fibrosis.


Avalyn is developing inhaled formulations of approved medications to treat rare respiratory diseases. Our initial focus is on the treatment of Interstitial Lung Diseases, including Pulmonary Fibrosis, and rare diseases that have dramatic impacts on patient quality of life.


May 13, 2024

Avalyn Announces Multiple Presentations on its Lead Program, AP01, for Pulmonary Fibrosis and its Approach to Developing Novel Inhaled Therapies for Lung Diseases at the 2024 American Thoracic Society International Conference
Read more »

May 1, 2024

Avalyn Bolsters Leadership Team with the Appointment of Douglas Carlson as Chief Financial Officer and Chief Business Officer
Read more »

March 6, 2024

Avalyn to Participate in Leerink Partners Global Biopharma Conference
Read more »

February 6, 2024

Avalyn to Participate in Multiple Upcoming Investor Conferences
Read more »